Healthcare provider profile · identity verified

Xin Wang, M.D.

Internal Medicine · TUALATIN, OR · NPI 1407160260

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	468	97
Eliquis	Apixaban	458	70
Levothyroxine Sodium	Levothyroxine Sodium	437	77
Gabapentin	Gabapentin	330	61
Furosemide	Furosemide	301	54
Potassium Chloride	Potassium Chloride	276	50
Metoprolol Succinate	Metoprolol Succinate	239	56
Amlodipine Besylate	Amlodipine Besylate	196	46
Duloxetine Hcl	Duloxetine Hcl	181	41
Lisinopril	Lisinopril	174	40
Losartan Potassium	Losartan Potassium	168	42
Tamsulosin Hcl	Tamsulosin Hcl	166	33
Metformin Hcl	Metformin Hcl	154	29
Clopidogrel	Clopidogrel Bisulfate	134	28
Pantoprazole Sodium	Pantoprazole Sodium	127	39
Trazodone Hcl	Trazodone Hcl	106	23
Carvedilol	Carvedilol	93	27
Torsemide	Torsemide	90	22
Escitalopram Oxalate	Escitalopram Oxalate	87	15
Sertraline Hcl	Sertraline Hcl	84	20
Finasteride	Finasteride	83	11
Metoprolol Tartrate	Metoprolol Tartrate	82	23
Jardiance	Empagliflozin	78	15
Mirtazapine	Mirtazapine	75	22
Arexvy	Rsvpref3 Antigen/As01e/Pf	70	68
Metformin Hcl Er	Metformin Hcl	64	11
Omeprazole	Omeprazole	59	12
Donepezil Hcl	Donepezil Hcl	56	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	56	16
Allopurinol	Allopurinol	52	11
Fluoxetine Hcl	Fluoxetine Hcl	52	16
Rosuvastatin Calcium	Rosuvastatin Calcium	52	11
Amiodarone Hcl	Amiodarone Hcl	48	15
Famotidine	Famotidine	48	suppressed
Ondansetron Odt	Ondansetron	48	18
Venlafaxine Hcl Er	Venlafaxine Hcl	48	suppressed
Ondansetron Hcl	Ondansetron Hcl	47	25
Citalopram Hbr	Citalopram Hydrobromide	46	suppressed
Lovastatin	Lovastatin	46	suppressed
Diclofenac Sodium	Diclofenac Sodium	45	12
Ropinirole Hcl	Ropinirole Hcl	44	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	42	suppressed
Levetiracetam	Levetiracetam	42	suppressed
Xarelto	Rivaroxaban	40	suppressed
Cephalexin	Cephalexin	39	20
Glipizide	Glipizide	39	suppressed
Montelukast Sodium	Montelukast Sodium	38	suppressed
Warfarin Sodium	Warfarin Sodium	37	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	34	14
Isosorbide Dinitrate	Isosorbide Dinitrate	34	suppressed
Myrbetriq	Mirabegron	34	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	33	20
Alendronate Sodium	Alendronate Sodium	33	suppressed
Naloxone Hcl	Naloxone Hcl	32	27
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	31	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	29	suppressed
Baclofen	Baclofen	28	suppressed
Levofloxacin	Levofloxacin	28	16
Oxybutynin Chloride	Oxybutynin Chloride	28	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	14
Divalproex Sodium	Divalproex Sodium	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Midodrine Hcl	Midodrine Hcl	26	suppressed
Insulin Aspart Flexpen	Insulin Aspart	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	13
Nifedipine Er	Nifedipine	24	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	23	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	23	suppressed
Prednisone	Prednisone	23	20
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Liothyronine Sodium	Liothyronine Sodium	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Carbamazepine Er	Carbamazepine	21	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	21	suppressed
Mesalamine	Mesalamine	21	suppressed
Methenamine Hippurate	Methenamine Hippurate	21	suppressed
Oxycodone Hcl	Oxycodone Hcl	21	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Lactulose	Lactulose	19	suppressed
Lamotrigine	Lamotrigine	19	suppressed
Latanoprost	Latanoprost	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	18
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Insulin Lispro	Insulin Lispro	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Calcium Acetate	Calcium Acetate	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	suppressed
Nystatin	Nystatin	17	13
Risperidone	Risperidone	17	suppressed
Azithromycin	Azithromycin	16	12
Ketoconazole	Ketoconazole	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Glycopyrrolate	Glycopyrrolate	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Budesonide	Budesonide	12	suppressed
Clonidine	Clonidine	12	suppressed
Entacapone	Entacapone	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Simvastatin	Simvastatin	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Fluconazole	Fluconazole	11	suppressed
Glimepiride	Glimepiride	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	11	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Ozempic	Semaglutide	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Travoprost	Travoprost	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error